Kam Zaki Profile picture
Medical Oncologist
May 30, 2020 24 tweets 14 min read
#ASCO20 summary for #LCSM Phase III ADAURA study showed adjuvant osimertinib improves DFS (HR 0.17) in respected stage II-III NCSLC, no OS data yet